UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): May 12, 2015
THERAVANCE BIOPHARMA, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Cayman Islands (State or Other Jurisdiction of Incorporation) |
|
001-36033 (Commission File Number) |
|
98-1226628 (I.R.S. Employer Identification Number) |
PO Box 309
Ugland House, South Church Street
George Town, Grand Cayman, Cayman Islands KY1-1104
(650) 808-6000
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Attached as Exhibit 99.1 to this report, and incorporated herein by reference, is a slide presentation, which was presented by Theravance Biopharma, Inc. at the Bank of America Merrill Lynch Health Care Conference Tuesday, May 12, 2015 in Las Vegas, NV.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Theravance Biopharma’s Investor Slide Presentation at Bank of America Merrill Lynch Health Care Conference on May 12, 2015
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
THERAVANCE BIOPHARMA, INC. | |
|
|
| |
|
|
| |
|
Date: May 12, 2015 |
By: |
/s/ Renee D. Gala |
|
|
|
Renee D. Gala |
|
|
|
Senior Vice President and Chief Financial Officer |